Mixed Topics
Latest News
New Cosmeceutical as Effective as Cysteamine for Facial Melasma
The product is a "new potent melanogenesis inhibitor that exhibits a unique mode of action while preserving melanocyte integrity," said Mukta...
From the Journals
Risk Assessment Tool Can Help Predict Fractures in Cancer
Researchers collected data on bone mineral density and fractures in 9,877 patients with cancer and 45,875 matched control individuals without...
Latest News
Topical JAK Inhibitor Shows Benefits in Small Frontal Fibrosing Alopecia Study
The slow progress to identify treatments for FFA is illustrated by the fact that only one other double-blind and randomized trial has ever been...
Latest News
Hidradenitis Suppurativa: Nodules Respond to As Needed Topical JAK Inhibitor
Entry criteria for the study included Hurley stage I or II HS with no draining tunnels. Hurley stage III patients were not eligible.
From the Journals
Is BMI Underestimating Breast Cancer Risk in Postmenopausal Women?
Researchers conducted a case-control study including 1,033 breast cancer cases and 1,143 postmenopausal population controls; both BMI and body fat...
Commentary
The New Cancer Stats Might Look Like a Death Sentence. They Aren’t.
Data show that people under 50 are experiencing higher rates of cancer than any generation before them.
Feature
How to Treat Cancer While Preserving Fertility
Some chemotherapies are known for their effects on oocytes, follicle maturation, and spermatogenesis, but knowledge about newer treatment options...
Latest News
Childhood-Onset Atopic Dermatitis Adds Burden in Adulthood
The Scars of Life project was designed to analyze how the age of AD onset affects the severity of symptoms and quality of life.
Feature
AACR Cancer Progress Report: Big Strides and Big Gaps
The report focused on strides made in cancer care, prevention, and early detection and highlighted areas where more research and attention are...
From the Journals
Cancer Risk: Are Pesticides the New Smoking?
A recent study evaluated cancer risks in the US population using a model that accounts for pesticide use and adjusts for various factors.
News from the FDA/CDC
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications
The drug combo was the first programmed death–ligand 1 inhibitor to gain approval for subcutaneous administration.